OVERVIEW 
This free activity, entitled "Cellular Metabolism in Hematologic Malignancies: From Evolving Science to Therapeutic Potential," consists of a program overview, 5 presentations with Q&A, a Learning Assessment, and an Evaluation form. The content of this virtual lecture is derived from a symposium presented on December 7, 2012, in Atlanta, GA.

MEDIUM: Virtual Lecture
INTERNET RELEASE DATE: February 28, 2013
CE AVAILABLE UNTIL: August 28, 2014
CME credit is no longer available for this activity.

Estimated time to complete this activity: 3.25 hours

     

---

TARGET AUDIENCE
This activity is designed for hematologists, oncologists, nurses, social workers and other healthcare professionals who wish to enhance their knowledge of advances in cellular metabolism and implications in treating patients with hematologic malignancies.

---

STATEMENT OF NEED
Over 80 years ago, world-renowned biochemist Otto Heinrich Warburg observed that cancer cells exhibited high glycolysis (glucose conversion to lactic acid) even in the presence of oxygen (Warburg effect). However, not until the last decade did the reprogramming of cellular metabolism regain deserved attention for its role in cancer.

A number of common oncogenes and tumor suppressor genes have been discovered that directly control cell metabolism. In addition, a number of metabolic enzymes causally mutated in a variety of human cancers including hematological malignancies have now been identified as human tumor suppressors or oncogenes. The reprogramming of metabolic pathways is essential for tumors to survive and proliferate in their microenvironment. As a result of these more recent developments, several pharmacologic therapies have been developed and are currently under evaluation in clinical trials for their safety and efficacy in the treatment of both solid and hematologic cancers.

Cancer cell metabolism and the Warburg effect are promising targets for cancer treatment. However, physicians may lack the clinical and biochemical knowledge of the basic science behind the Warburg effect. In addition, physicians may not be up-to-date on the agents that are currently under evaluation in clinical trials. Some of these agents are in late-stage clinical trials and have demonstrated promising results. Therefore, it is important that physicians understand the basic science of the Warburg effect and the emerging pharmacologic agents that may reach the clinic, which may provide important additional options for the treatment of cancer. This knowledge will allow physicians to effectively implement these new therapies in their clinical practice, potentially improving patient outcomes and quality of life.

---

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Describe how metabolic reprogramming contributes to tumor transformation and sustains progression in blood cancer cells
• Assess the therapeutic potential of targeting metabolic changes as they relate specifically to hematologic malignancies
• Apply new strategies for incorporating therapies that target metabolism in blood cancers
• Utilize the information presented from current and future clinical trials that evaluate cancer metabolism in order to better manage patients with hematologic malignancies
• Explain the basis for therapies that affect cancer cell metabolism

---

FACULTY

Chi V. Dang, MD, PhD
John H. Glick, MD, Professor of Medicine
Director, Abramson Cancer Center
University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Jeffrey C. Rathmell, PhD
Associate Professor
Department of Pharmacology and Cancer Biology
Department of Immunology
Sarah W. Stedman Nutrition and Metabolism Center
Duke University
Durham, NC

Mariusz A. Wasik, MD
Professor
Department of Pathology
University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Ayalew Tefferi, MD
Professor of Medicine
Division of Hematology
Mayo Clinic
Rochester, MN

John L. Cleveland, PhD
Professor and Chair
Department of Cancer Biology
The Scripps Research Institute
Jupiter, FL

---

PHYSICIAN CONTINUING EDUCATION INFORMATION
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Leukemia & Lymphoma Society, RMEI, LLC and Postgraduate Institute for Medicine. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

---

METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this activity. During the period February 28, 2013, through February 28, 2014, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on "Find Post-Test/Evaluation by Course" and search by course ID 8934. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

---

CONTINUING EDUCATION INFORMATION FOR NURSES AND SOCIAL WORKERS
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under provider number CEP 5832 to award 3.25 continuing education contact hours through the California Board of Registered Nursing.

The Leukemia & Lymphoma Society (LLS), provider number 1105, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org Approved Continuing Education Program (ACE). Approval Period: December 2011 – December 2014. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval. Social workers will receive 3.25 CE clinical clock hours.

Upon successful completion of the entire program, post-test (grade of 70% or higher) and submission of the activity evaluation, a certificate of completion will be issued to you within 30 days, via e-mail or US mail based on your designation on the evaluation.

---

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

• John L. Cleveland, PhD, has no affiliations with commercial interests to disclose.
• Chi V. Dang, MD, PhD, has no affiliations with commercial interests to disclose.
• Jeffrey C. Rathmell, PhD, has affiliations with Lycera (Consulting Fees).
• Ayalew Tefferi, MD, has no affiliations with commercial interests to disclose.
• Mariusz A. Wasik, MD, has no affiliations with commercial interests to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

THE LEUKEMIA & LYMPHOMA SOCIETY

• Richard C. Winneker, PhD, has no affiliations with commercial interests to disclose.

RMEI, LLC

• Cynthia M. Kunzer has no affiliations with commercial interests to disclose.
• Emma Hitt, PhD, has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine

The following PIM staff serve as clinical content reviewers and/or participate in planning CME/CE activities in a manner that may affect content: Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP; and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.

---

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

---

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information and comparison with recommendations of other authorities.

---

STATEMENT OF SUPPORT
This activity is jointly sponsored by The Leukemia & Lymphoma Society, RMEI, LLC and Postgraduate Institute for Medicine and supported by an educational grant from Celgene Corporation.

---

FEE INFORMATION
There is no fee for this educational activity.

---

QUESTIONS AND TECHNICAL ASSISTANCE
For questions regarding the content of this activity, contact the Information Resource Center (IRC) at 800-955-4572, or visit the LLS website at www.LLS.org. For technical assistance, contact jungsen@rmcom.net.

---

SYSTEM REQUIREMENTS
Hardware/Software requirements include:
• Windows XP, 2000, Vista, Windows 7   
  - Internet Explorer 6.0+
• Macintosh 9.2, OS X 10.1+
  - Safari 4+
• Additional Requirements
  - Adobe Flash Player 10
  - Internal/external speakers
  - Broadband connection (DSL/cable) recommended

 

 

RMEI Privacy Statement

Questions, grievances, assistance for people with disabilities or for more information on LLS programs, please contact an LLS Information Specialist at (800) 955-4572.